Literature DB >> 25183562

Hypertensive patients using thiazide diuretics as primary stroke prevention make better functional outcome after ischemic stroke.

Hong-Mo Shih1, Wei Chun Lin1, Cheng-Hsien Wang1, Leng-Chieh Lin2.   

Abstract

BACKGROUND: Thiazides have been used for the control of blood pressure and primary prevention of ischemic stroke. No previous studies have assessed the influence of thiazides on functional prognosis after ischemic stroke.
METHODS: Demographics, prestroke conditions, poststroke National Institutes of Health Stroke Scale score, and clinical and laboratory parameters were prospectively registered in 216 Taiwanese patients. One hundred forty patients who completed follow-up 3 months after experiencing ischemic stroke were assessed with the modified Rankin scale as functional prognoses.
RESULTS: Twenty-one patients used thiazide to control hypertension before experiencing ischemic stroke. No differences of stroke subtypes and comorbidities before stroke were observed between the 2 groups. The emergency department National Institutes of Health Stroke Scale was lesser among thiazide users (4 [2-7] versus 6 [4-16], P = .02). Among 140 patients who completed follow-up in 90 days, thiazide users had more favorable functional status (modified Rankin scale ≤2: 42.4% versus 26.9%, P = .02, odds ratio 3.34, 95%, confidence interval .130-.862).
CONCLUSION: Hypertensive patients treated with thiazides long term had a lesser severity of stroke and better functional outcomes after ischemic stroke.
Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Thiazide-diuretics; functional prognosis; hypertension; ischemic stroke; stroke in evolution; stroke primary prevention

Mesh:

Substances:

Year:  2014        PMID: 25183562     DOI: 10.1016/j.jstrokecerebrovasdis.2014.05.021

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  1 in total

1.  Diuretics and cerebrovascular outcomes--beyond traditional endpoints.

Authors:  Magnus Wijkman
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-02-09       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.